U. Alshüth

940 total citations
31 papers, 678 citations indexed

About

U. Alshüth is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, U. Alshüth has authored 31 papers receiving a total of 678 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hepatology, 21 papers in Epidemiology and 5 papers in Infectious Diseases. Recurrent topics in U. Alshüth's work include Hepatitis C virus research (30 papers), Liver Disease Diagnosis and Treatment (16 papers) and Hepatitis B Virus Studies (14 papers). U. Alshüth is often cited by papers focused on Hepatitis C virus research (30 papers), Liver Disease Diagnosis and Treatment (16 papers) and Hepatitis B Virus Studies (14 papers). U. Alshüth collaborates with scholars based in Germany, Switzerland and United States. U. Alshüth's co-authors include Stefan Mauss, Peter Buggisch, D. Hueppe, Christoph Sarrazin, Thomas Berg, B. Kallinowski, Stefan Zeuzem, Michael Wagner, Ulrich Spengler and Samer Nasser and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

U. Alshüth

29 papers receiving 657 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
U. Alshüth Germany	10	603	585	75	62	31	31	678
Mauro Annese Italy	10	979 1.6×	916 1.6×	76 1.0×	83 1.3×	34 1.1×	14	1.0k
Riina Salupere Estonia	6	593 1.0×	561 1.0×	112 1.5×	36 0.6×	16 0.5×	12	706
Angie Price United States	8	394 0.7×	341 0.6×	69 0.9×	16 0.3×	25 0.8×	13	498
J.-P. Zarski France	8	650 1.1×	586 1.0×	30 0.4×	149 2.4×	29 0.9×	14	719
Oscar G. Mandό Argentina	12	192 0.3×	195 0.3×	76 1.0×	18 0.3×	29 0.9×	21	350
Mario Romano Italy	7	920 1.5×	849 1.5×	85 1.1×	91 1.5×	39 1.3×	9	962
William N. Katkov United States	10	231 0.4×	329 0.6×	27 0.4×	43 0.7×	11 0.4×	17	469
Hironori Tanimoto Japan	7	350 0.6×	307 0.5×	26 0.3×	50 0.8×	9 0.3×	18	388
T Sodeyama Japan	10	464 0.8×	439 0.8×	43 0.6×	31 0.5×	7 0.2×	19	536
Magdy El‐Serafy Egypt	10	354 0.6×	312 0.5×	29 0.4×	18 0.3×	7 0.2×	39	438

Countries citing papers authored by U. Alshüth

Since Specialization

Citations

This map shows the geographic impact of U. Alshüth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by U. Alshüth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites U. Alshüth more than expected).

Fields of papers citing papers by U. Alshüth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by U. Alshüth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by U. Alshüth. The network helps show where U. Alshüth may publish in the future.

Co-authorship network of co-authors of U. Alshüth

This figure shows the co-authorship network connecting the top 25 collaborators of U. Alshüth. A scholar is included among the top collaborators of U. Alshüth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with U. Alshüth. U. Alshüth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Marcellin, Patrick, Qing Xie, Seung Woon Paik, et al.. (2020). Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. PLoS ONE. 15(4). e0230893–e0230893. 7 indexed citations

Witzke, Oliver, Martin Nitschke, Michael Bartels, et al.. (2017). Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients. Transplantation. 102(5). 876–882. 46 indexed citations

Wedemeyer, Heiner, Jens Reimer, D. Hueppe, et al.. (2017). Long‐term outcome of chronic hepatitis C virus infection in a real‐world setting: The German LOTOS study. Liver International. 37(10). 1468–1475. 6 indexed citations

Zimmermann, Tim, D. Hueppe, Stefan Mauss, et al.. (2016). Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1. Journal of Gastrointestinal and Liver Diseases. 25(1). 15–24. 4 indexed citations

Hofmann, Wolf Peter, Stefan Mauss, Thomas A. Lutz, et al.. (2015). Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. PLoS ONE. 10(7). e0134839–e0134839. 4 indexed citations

Stahmeyer, Jona T., Christian Krauth, U. Alshüth, et al.. (2015). Costs and outcomes of treating chronic hepatitis C patients in routine care – results from a nationwide multicenter trial. Journal of Viral Hepatitis. 23(2). 105–115. 10 indexed citations

Fülöp, B, Michael Biermer, Markus Cornberg, et al.. (2015). Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa‐2a in hepatitis C null responders. Liver International. 35(10). 2275–2284. 1 indexed citations

Niederau, Claus, Stefan Mauss, Andreas Schober, et al.. (2014). Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3. PLoS ONE. 9(9). e107592–e107592. 12 indexed citations

Hofmann, W, Axel Baumgarten, Klaus Boeker, et al.. (2014). P1150 BASELINE CHARACTERISTICS AND TREATMENT EFFICACY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2a AND RIBAVIRIN IN 253 HCV GENOTYPE 1 NONRESPONDER PATIENTS IN A REAL-WORLD SETTING. Journal of Hepatology. 60(1). S466–S466.

10.

Stahmeyer, Jona T., S. Rossol, Ahmed Abdelfattah, et al.. (2013). Epidemiology, Treatment Outcomes and Costs of Treating Hepatitis C in Routine Care – Results from a Large Multicenter Trial. Value in Health. 16(7). A341–A342. 2 indexed citations

11.

Mauss, Stefan, Klaus H.W. Böker, Thomas A. Lutz, et al.. (2013). Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice. European Journal of Gastroenterology & Hepatology. 26(1). 65–73. 3 indexed citations

12.

Mauss, Stefan, D. Hueppe, & U. Alshüth. (2013). Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology. 59(1). 46–48. 59 indexed citations

13.

Spengler, Ulrich, C John, R Heyne, et al.. (2013). 908 REAL-WORLD EFFICACY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY. Journal of Hepatology. 58. S374–S374. 1 indexed citations

14.

Boeker, Klaus, Christoph Eisenbach, Bernd Moeller, et al.. (2013). 871 REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY. Journal of Hepatology. 58. S357–S358. 1 indexed citations

15.

Hueppe, D., Stefan Mauss, Andreas Schober, et al.. (2013). Prädiktive Baseline Faktoren bei Patienten mit Zirrhose für den Therapieerfolg einer dualen Therapie mit Peginterferon alfa-2a (PEG) plus Ribavirin (RBV), was zählt?. Zeitschrift für Gastroenterologie. 51(8). 1 indexed citations

16.

Mauss, Stefan, D. Hueppe, Ulrich Spengler, et al.. (2013). Sa1041 Triple Therapy Under Real Life Conditions: Telaprevir (TVR) and Boceprevir (BOC) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in Treatment Experienced Patients Infected With Chronic Hepatitis C, Genotype 1. the PAN Study. Gastroenterology. 144(5). S–980. 3 indexed citations

17.

Mauss, Stefan, F. Berger, Michael Vogel, et al.. (2012). Treatment Results of Chronic Hepatitis C Genotype 5 and 6 Infections in Germany. Zeitschrift für Gastroenterologie. 50(5). 441–444. 24 indexed citations

18.

Lutz, Tracey, Axel Baumgarten, Christoph Eisenbach, et al.. (2011). 447 DIFFERENCES IN DEMOGRAPHICS AND TREATMENT OUTCOME OF CHRONIC HEPATITIS C (CHC) PATIENTS OF DIFFERENT EUROPEAN ORIGIN TREATED WITH PEGINTERFERON ALFA-2A (40KDA) AND RIBAVIRIN (PEG/RBV). Journal of Hepatology. 54. S182–S182.

19.

Witthöft, T, B Möller, K. H. Wiedmann, et al.. (2007). Safety, tolerability and efficacy of peginterferon alpha‐2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. Journal of Viral Hepatitis. 14(11). 788–796. 44 indexed citations

20.

Berg, Thomas, Michael Wagner, Samer Nasser, et al.. (2006). Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin. Gastroenterology. 130(4). 1086–1097. 368 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact